Single Hormone Closed Loop Study With PDT Sensor

Exclusion Criteria

• •Female of childbearing potential who is pregnant or intending to become pregnant or breast-feeding, or is not using adequate contraceptive methods. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence.
• •Any cardiovascular disease, defined as a clinically significant EKG abnormality at the time of screening or any history of: stroke, heart failure, myocardial infarction, angina pectoris, or coronary arterial bypass graft or angioplasty. Diagnosis of 2nd or 3rd degree heart block or any non-physiological arrhythmia judged by the investigator to be exclusionary.
• •Renal insufficiency (GFR \< 60 ml/min, using the MDRD equation as reported by the OHSU laboratory).
• •Liver failure, cirrhosis, or any other liver disease that compromises liver function as determined by the investigator.
• •Hematocrit of less than 36% for men, less than 32% for women.
• •History of severe hypoglycemia during the past 12 months prior to screening visit or hypoglycemia unawareness as judged by the investigator.
• •History of Diabetic Ketoacidosis during the prior 6 months prior to screening visit, as diagnosed on hospital admission or as judged by the investigator.
• •Adrenal insufficiency.
• •Any active infection.
• •Known or suspected abuse of alcohol, narcotics, or illicit drugs.
• •Seizure disorder.
• •Active foot ulceration.
• •Severe peripheral arterial disease characterized by ischemic rest pain or severe claudication.
• •Major surgical operation within 30 days prior to screening.
• •Use of an investigational drug within 30 days prior to screening.
• •Chronic usage of any immunosuppressive medication (such as cyclosporine, azathioprine, sirolimus, or tacrolimus).
• •Bleeding disorder, treatment with warfarin, or platelet count below 50,000.
• •Allergy to lispro insulin.
• •Allergy to acrylate-based skin adhesives.
• •Need for uninterrupted treatment of acetaminophen.
• •Current administration of oral or parenteral corticosteroids.
• •Any life threatening disease, including malignant neoplasms and medical history of malignant neoplasms within the past 5 years prior to screening (except basal and squamous cell skin cancer).
• •Beta blockers or non-dihydropyridine calcium channel blockers.
• •Current use of any medication intended to lower glucose other than insulin (ex. use of liraglutide).
• •Any clinically significant disease or disorder which in the opinion of the Investigator may jeopardize the subject's safety or compliance with the protocol.